William, William N.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,086

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 965

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 646

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 618

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 387

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy

William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 138

Sleep-Related Breathing Disorders in Patients With Tumors in the Head and Neck Region

Faiz, S. A., Balachandran, D., Hessel, A. C., Lei, X., Beadle, B. M., William, W. N., & Bashoura, L. (2014) · The Oncologist

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 68

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer

Cascone, T., Gold, K. A., Swisher, S. G., Liu, D. D., Fossella, F. V., Sepesi, B., Pataer, A., Weissferdt, A., Kalhor, N., Vaporciyan, A. A., et al. (2018) · The Annals of Thoracic Surgery

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 32

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 31

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer

Sepesi, B., Godoy, M., William, W., Vaporciyan, A., Lin, H., Leung, C., Lee, J., Mitchell, K., Weissferdt, A., Le, X., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 14